- €14.19bn
- €19.11bn
- €3.54bn
Brief: Sartorius Confirms FY Outlook
Brief: Sartorius 9M EBITDA EUR 686.5 Million
Stifel adjusts ratings on European pharma; downgrades Sartorius, Siegfried ahead of H2
Brief: Sartorius AG - Sartorius And G-Con Collaborate To Deliver Sustainable, Flexible Cgmp Facilities Faster
RBC ups Sartorius, Stedim Biotech as shares underperformance provides an opportunity
Europe Research Roundup: Draegerwerk, Hikma, Novartis
Tecan's guidance cut dents peers Sartorius, Stedim Biotech shares
Top of the Street: Eni, Sartorius Stedim Biotech, Sartorius
Bernstein starts Sartorius, unit Stedim with 'underperform' on 2028 outlook risks
Swiss pharma firm Lonza posts lower half-year profit (updated)
Sartorius jumps as peer Danaher posts Q2 profit beat
Sartorius slips in early trade after guidance cut
Sartorius cuts annual profit margin outlook on lower lab equipment demand (updated)
Sartorius cuts annual profit margin outlook on lower lab equipment demand
Brief: Sartorius Sees Sales Revenue Is Now Forecast To Be Around 12 % In 2024
Brief: Sartorius cuts full year guidance and reports H1 results
Sartorius falls after it announces CEO stepping down
Brief: Sartorius Says CEO Kreuzburg Will Not Pursue Another Term In Office
UK inflation back to 2% target for first time since 2021 (updated)